CN101095672B - Novel pharmacy use of medicinal composition - Google Patents
Novel pharmacy use of medicinal composition Download PDFInfo
- Publication number
- CN101095672B CN101095672B CN2007101194269A CN200710119426A CN101095672B CN 101095672 B CN101095672 B CN 101095672B CN 2007101194269 A CN2007101194269 A CN 2007101194269A CN 200710119426 A CN200710119426 A CN 200710119426A CN 101095672 B CN101095672 B CN 101095672B
- Authority
- CN
- China
- Prior art keywords
- tumor
- catechin
- tea polyphenols
- pharmaceutical compositions
- control rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses the novel use of four kinds of medicinal compositions of catechin in preparing pharmaceuticals, the antineoplastic preparation prepared from a specific proportion of the catechin pharmaceutical compositions has better therapeutic effects.
Description
Technical field
The present invention relates to a kind of new pharmaceutical use of pharmaceutical composition, particularly the new pharmaceutical use of catechin pharmaceutical composition.
Background technology
Put down in writing tea polyphenols (Tea Polyphenols) in the existing document and four kinds of catechins have extensive anti-tumor activity, but still do not had the relevant report of the mutual combined preparation antitumor drug of catechin composition.
Summary of the invention
The object of the invention is to provide a kind of new pharmaceutical use of pharmaceutical composition, particularly the new pharmaceutical use of catechin pharmaceutical composition.
The present invention seeks to be achieved through the following technical solutions:
Catechin pharmaceutical composition of the present invention is used to prepare the medicine with antitumor action.
EGCG:EGC=5-15:1 in the catechin pharmaceutical composition of the present invention, preferred 9:1,7:1,12:1; Or EGC:ECG=1-5:1, preferred 3:1,2:1,4:1; Or ECG:EC=0.5-1.5:1, preferred 1:1,0.6:1,1.2:1.
EGCG is that epigallocatechin gallate (EGCG), EGC are that epigallo catechin, ECG are that L-Epicatechin gallate, EC are epicatechin in the invention described above catechin pharmaceutical composition.
Catechin pharmaceutical composition of the present invention is the known material with pharmaceutically active of a class, therefore can be on the basis of said ratio, formulation method according to routine, it is prepared into the clinical any medicament that can be used for treating malignant tumor, includes but not limited to: capsule, pill (drop pill), tablet, granule, oral liquid or injection.
In the process of the above-mentioned preparation of preparation, catechin pharmaceutical composition and any mixed with excipients that is prepared into clinical medicament that is applicable to can be used, be prepared into pharmaceutical preparation.
Through experimental results show that: EGCG and EGC are higher than tea polyphenols to various transplanted tumor suppression ratio when the 5-15:1 ratio, wherein, especially remarkable for the tumor control rate effect of melanoma piece class transplanted tumor; EGC and the ECG suppression ratio to various transplanted tumors when the 1-5:1 ratio is higher than tea polyphenols, and is wherein, especially remarkable for the tumor control rate effect of breast carcinoma class transplanted tumor; ECG and the EC suppression ratio to various transplanted tumors when the 0.5-1.5:1 ratio is higher than the tea polyphenols group, and is wherein, especially remarkable for the tumor control rate effect of ascites tumor class transplanted tumor.
Following experiment and embodiment are used to further specify but are not limited to the present invention.
1 four kinds of catechin anti-transplant tumor experiments of experimental example
Tea polyphenols (Tea Polyphenols) also claim catechin, is grouped into by 4 kinds of one-tenth, that is: epigallocatechin gallate (EGCG) (EGCG), epigallo catechin (EGC), L-Epicatechin gallate (ECG), epicatechin (EC).The highest with epigallocatechin gallate (EGCG) (EGCG) content, account for 50% of catechin.Whether we carry out specific compatibility with four kinds of compositions of tea polyphenols on tea polyphenols anti-tumor experiment basis, have to strengthen and press down the tumor effect to observe it.
1 material
1.1 animal
Animal strain, source, raising condition are as follows: 1. 6～8 age in week SPF level BALB/C-nu nude mice, male and female half and half are bred and are provided that (produce the quality certification number: the capital is moving is betrothed to (1999) No. 015 by laboratory animal room of Tumour Inst., Chinese Medical Academy; The animal quality certification number: SCXK capital 2004-0006), be aided with in the clean laminar flow cabinet environment in Tumour Inst., Chinese Medical Academy's zoopery center shielding harness and raise.2. male C57 kind mice, body weight 20 ± 2g buys by Beijing Vital River Experimental Animals Technology Co., Ltd. (quality certification number: the capital is moving is betrothed to 004049), raises under the cleaning level environment of first key lab of clinical medicine institute of Beijing University of Chinese Medicine.3. male ICR mouse, body weight 18～20g provides (credit number: SYXK (Soviet Union) 2002-0053) by Nanjing University of Traditional Chinese Medicine's Experimental Animal Center, raises under preclinical medicine institute of Nanjing University of Traditional Chinese Medicine animal center cleaning level environment.4. female BALB/c mouse, body weight (20 ± 2) g available from Shanghai Si Kelai laboratory animal company limited [credit number: SCXK (Shanghai) 2003-0003], raises under the animal center barrier system SPF of Nanjing University of Traditional Chinese Medicine environment.
1.2 cell line and tumor piece
Human lung adenocarcinoma A549 preserves and provides by inspection center of Tumour Inst., Chinese Medical Academy is conventional; Murine melanoma piece (B16) is provided by the Tumour Inst., Chinese Medical Academy experimental center; The S180 tumor cell line is provided by central laboratory of preclinical medicine institute of Nanjing University of Traditional Chinese Medicine; Mouse breast cancer (EMT
6) mouse mammary carcinoma cell line is available from The Fourth Military Medical University of P.L.A's Experimental Animal Center.
1.3 medicine and instrument
The tea polyphenols that four kinds of catechins are so kind as to give by Jiangxi Lv Kang natural product Co., Ltd separates and gets; Superclean bench is the grand auspicious purification Science and Technology Ltd.'s production in Suzhou (model SCW-CJ); Experiment is that the permanent auspicious pharmaceutical machine company limited in Jiangsu is produced (model LS150) with centrifuge; Inverted microscope is Japanese NIKON Co., Ltd.'s production (model TS100); Slide gauge is that Chinese Hangzhou Tool and Measuring Meas Co., Ltd produces (model HGL-18-1); Ao Haosi precise electronic balance is a U.S. OHAUS company product (model ARA520); The Forma constant incubator is a U.S. Forma company product (model 3111).
2 methods
2.1 cell culture and inoculation
Different tumor cell culture and inoculation method are as follows: 1. A549 cultivates eventually at the DMEM culture fluid that contains 10% calf serum, cell is used 0.25% trypsinization after covering with monolayer, culture fluid piping and druming, centrifugal, collecting cell dilutes with PBS, transfers cell concentration to 1 * 10
7Individual/ml, it is subcutaneous that every mice is inoculated in right axil with 0.2ml, and tumor is grown to volume and is about 1000mm
3Shi Yizhi.2. select to cultivate the S in 1 week
180The ascites tumor mice extracts milky ascites, adds the tumor cell suspension that normal saline is diluted to 1: 4 in right amount, transfers cell number to 1 * 10
8Individual/ml, every Mus kind 0.2ml is under the right fore axillary fossa, and whole inoculation time was finished in 1 hour.3. EMT
6Cell is cultivated with the RMPI RPMI-1640 that contains 10% calf serum, and cell is used 0.25% trypsinization after covering with monolayer, and culture fluid piping and druming is centrifugal, and collecting cell dilutes with PBS, and concentration transfers to 5 * 10
6, every mice is inoculated in the right back back of mice with 0.2ml.Transplant when tumor is grown to 1g behind the 12d.4. melanoma (B
16) tumor-bearing mice, aseptic condition takes out the tumor piece down, adds PBS and is prepared into single cell suspension with glass homogenizer by the 1:4 dilution, adjusts cell number and is about 5 * 10
6Individual/ml, getting 0.2ml respectively, to be inoculated in C57 mice right fore axillary fossa subcutaneous, and inoculation time is finished in 1h.
2.2 experiment grouping
According to the document modeling at S180, EMT6), divide into groups respectively after four kinds of transplanted tumor modelings of A549, B16, promptly every kind of tumor model divides epigallocatechin gallate (EGCG) (EGCG), epigallo catechin (EGC), L-Epicatechin gallate (ECG), epicatechin (EC) four to organize greatly.Every big group is divided high, medium and low three dosage groups again.
2.3 dosage and method
With reference to tea polyphenols experiment dosage, that is: the heavy dose of EGCG, EGC, ECG, EC is 6.75mg/d, and middle dosage is that 2.25mg/d, low dosage are 0.75mg/d.Each experimental group all adopts the gastric infusion approach.
2.4 computational methods
Experiment finishes the back and puts to death tumor-bearing mice, peels off tumor rapidly and weighs, and calculate tumor control rate as follows, that is: tumour inhibiting rate (%)=average tumor of (it is heavy that average tumor is organized in the average tumor weight-treatment of matched group)/matched group heavy * 100%.
2.5 statistical method
All The data SPSS14.0 statistical softwares handle, and enumeration data adopts x ± s to represent; Many groups data mean relatively adopts one factor analysis of variance, and when P＜0.05, expression has statistical significance.
3 results
3.1 four kinds of catechin tumour inhibiting rates: the tumor control rate of four kinds of catechins sees Table 1.
Tumor control rate (%) is respectively organized in table 1. experiment
And high dose compares between group, * P＜0.05
As can be seen from Table 1, EGCG, EGC, four kinds of catechins of ECG, EC all have in various degree inhibition effect to S180, EMT6, A549, B16 transplanted tumor, but best with the high dose group tumour inhibiting rate, middle dosage takes second place.
3.2 catechin and tea polyphenols tumour inhibiting rate:
Relatively see Table 2-table 4 according to one, four kind of catechin of experiment and tea polyphenols tumour inhibiting rate.
Table 2.EGCG, tea polyphenols high dose tumor control rate
Compare with Tea Polyphenols,
*P＜0.05,
△P＜0.01
As can be seen from Table 2, tea polyphenols, four kinds of catechin high doses compare, and it is obvious to press down the tumor effect with tea polyphenols, compares not statistically significant mutually between four kinds of catechins.
The dosage tumor control rate compares (%) in table 3.EGC, the tea polyphenols
Compare with Tea Polyphenols,
*P＜0.05,
△P＜0.01
As can be seen from Table 3, in tea polyphenols, the four kinds of catechins dosage relatively, it is obvious also to press down the tumor effect with tea polyphenols; Compare not statistically significant between four kinds of catechin groups.
4.ECG, tea polyphenols low dosage tumor control rate relatively (%)
Compare with Tea Polyphenols,
*P＜0.05
As can be seen from Table 4, in tea polyphenols, the four kinds of catechins dosage relatively, except that EGC has the statistical significance the suppression ratio of S180, other each groups are not statistically significant relatively all; Compare not statistically significant between four kinds of catechin groups.
4 conclusions
According to the tea polyphenols dosage, four kinds of high, medium and low dosage of catechin all has to a certain degree depression effect to transplanted tumor, but suppresses effect not as good as the various dosage groups of tea polyphenols.Compare not statistically significant between four kinds of catechin groups.
The specific compatibility anti-transplant tumor experiment of experimental example 2 catechins
By experiment the result of example 1 as can be seen, 4 kinds of high, medium and low dosage groups of catechin all have to a certain degree depression effect, suppression ratio no significant difference to transplanted tumor; But four kinds of each dosage groups of a catechin and tea polyphenols dosage group relatively, and is obvious with the tea polyphenols tumor killing effect.Therefore, this experimental example mainly is that four kinds of catechins are carried out the suppression ratio of various combination observation to various transplanted tumors.
1 experiment material
1.1 animal
Animal strain, source, raising condition are as follows: 1. 6～8 age in week SPF level BALB/C-nu nude mice, male and female half and half are bred and are provided that (produce the quality certification number: the capital is moving is betrothed to (1999) No. 015 by laboratory animal room of Tumour Inst., Chinese Medical Academy; The animal quality certification number: SCXK capital 2004-0006), be aided with in the clean laminar flow cabinet environment in Tumour Inst., Chinese Medical Academy's zoopery center shielding harness and raise.2. male C57 kind mice, body weight 20 ± 2g buys by Beijing Vital River Experimental Animals Technology Co., Ltd. (quality certification number: the capital is moving is betrothed to 004049), raises under the cleaning level environment of first key lab of clinical medicine institute of Beijing University of Chinese Medicine.3. male ICR mouse, body weight 18～20g provides (credit number: SYXK (Soviet Union) 2002-0053) by Nanjing University of Traditional Chinese Medicine's Experimental Animal Center, raises under preclinical medicine institute of Nanjing University of Traditional Chinese Medicine animal center cleaning level environment.4. female BALB/c mouse, body weight (20 ± 2) g available from Shanghai Si Kelai laboratory animal company limited [credit number: SCXK (Shanghai) 2003-0003], raises under the animal center barrier system SPF of Nanjing University of Traditional Chinese Medicine environment.
1.2 cell line and tumor piece
Human lung adenocarcinoma A549 preserves and provides by inspection center of Tumour Inst., Chinese Medical Academy is conventional; Murine melanoma piece (B16) is provided by the Tumour Inst., Chinese Medical Academy experimental center; The S180 tumor cell line is provided by central laboratory of preclinical medicine institute of Nanjing University of Traditional Chinese Medicine; Mouse breast cancer (EMT
6) mouse mammary carcinoma cell line is available from The Fourth Military Medical University of P.L.A's Experimental Animal Center.
1.3 medicine and instrument
The tea polyphenols that four kinds of catechins are so kind as to give by Jiangxi Lv Kang natural product Co., Ltd separates and gets; Superclean bench is the grand auspicious purification Science and Technology Ltd.'s production in Suzhou (model SCW-CJ); Experiment is that the permanent auspicious pharmaceutical machine company limited in Jiangsu is produced (model LS150) with centrifuge; Inverted microscope is Japanese NIKON Co., Ltd.'s production (model TS100); Slide gauge is that Chinese Hangzhou Tool and Measuring Meas Co., Ltd produces (model HGL-18-1); Ao Haosi precise electronic balance is a U.S. OHAUS company product (model ARA520); The Forma constant incubator is a U.S. Forma company product (model 3111).
2 methods
2.1 cell culture and inoculation
Different tumor cell culture and inoculation method are as follows: 1. A549 cultivates eventually at the DMEM culture fluid that contains 10% calf serum, cell is used 0.25% trypsinization after covering with monolayer, culture fluid piping and druming, centrifugal, collecting cell dilutes with PBS, transfers cell concentration to 1 * 10
7Individual/ml, it is subcutaneous that every mice is inoculated in right axil with 0.2ml, and tumor is grown to volume and is about 1000mm
3Shi Yizhi.2. select to cultivate the S in 1 week
180The ascites tumor mice extracts milky ascites, adds the tumor cell suspension that normal saline is diluted to 1: 4 in right amount, transfers cell number to 1 * 10
8Individual/ml, every Mus kind 0.2ml is under the right fore axillary fossa, and whole inoculation time was finished in 1 hour.3. EMT
6Cell is cultivated with the RMPI1640 culture fluid that contains 10% calf serum, and cell is used 0.25% trypsinization after covering with monolayer, and culture fluid piping and druming is centrifugal, and collecting cell dilutes with PBS, and concentration transfers to 5 * 10
6, every mice is inoculated in the right back back of mice with 0.2ml.Transplant when tumor is grown to 1g behind the 12d.4. melanoma (B
16) tumor-bearing mice, aseptic condition takes out the tumor piece down, adds PBS and is prepared into single cell suspension with glass homogenizer by the 1:4 dilution, adjusts cell number and is about 5 * 10
6Individual/ml, getting 0.2ml respectively, to be inoculated in C57 mice right fore axillary fossa subcutaneous, and inoculation time is finished in 1h.
2.2 experiment grouping
Four kinds of catechins are carried out various combination to observe its suppression ratio to various transplanted tumors.
2.3 dosage and method
With reference to tea polyphenols experiment dosage, that is: the heavy dose of EGCG, EGC, ECG, EC is 6.75mg/d, and middle dosage is that 2.25mg/d, low dosage are 0.75mg/d.Each experimental group all adopts the gastric infusion approach.
2.4 computational methods
Experiment finishes the back and puts to death tumor-bearing mice, peels off tumor rapidly and weighs, and calculate tumor control rate as follows, that is: tumour inhibiting rate (%)=average tumor of (it is heavy that average tumor is organized in the average tumor weight-treatment of matched group)/matched group heavy * 100%.
2.5 statistical method
All The data SPSS14.0 statistical softwares handle, and enumeration data adopts x ± s to represent; Many groups data mean relatively adopts one factor analysis of variance, and when P＜0.05, expression has statistical significance.
3 results
Through the screening of preliminary experiment repeatedly, and be object of reference, observe the different catechin combination and whether have obvious synergistic effect that the catechin best of breed that is higher than the tea polyphenols tumour inhibiting rate through experiment sees the following form 5 with the tea polyphenols high dose group.
The tumor control rate of the different catechin particular combinations of table 5 and the contrast of tea polyphenols various dose
Compare with Tea Polyphenols,
*P＜0.05
4 conclusions
Through experiment repeatedly, EGCG high dose and the combination of EGC low dosage are higher than the tea polyphenols high dose group to various transplanted tumor suppression ratio; The combination of dosage group is higher than the tea polyphenols high dose group to the suppression ratio of various transplanted tumors among EGC high dose group and the ECG; ECG high dose group and the combination of EC high dose group are higher than the tea polyphenols group to the suppression ratio of various transplanted tumors.
Following embodiment all can realize the effect of above-mentioned experimental example.
The specific embodiment
Embodiment 1:
Get EGCG900g, EGCI00g adds conventional adjuvant, according to common process, makes capsule, is used for the treatment of tumor; Wherein, every pastille 0.45g; Each 1, every day 2 times.
Embodiment 2:
Get EGCG840g, EGC120g adds conventional adjuvant, according to common process, makes drop pill, is used for the treatment of tumor; Wherein, every ball pastille 0.042g; Each 10 balls, every day 2 times.
Embodiment 3:
Get EGCG720g, EGC60g adds conventional adjuvant, according to common process, makes oral liquid, is used for the treatment of tumor; Wherein, every pastille 0.36g; Each 1, every day 2 times.
Embodiment 4:
Get EGCG900g, EGC150g adds conventional adjuvant, according to common process, makes granule, is used for the treatment of tumor; Wherein, every bag of pastille 0.45g; Each 1 bag, every day 2 times.
Embodiment 5:
Get EGCG840g, EGC60g adds conventional adjuvant, according to common process, makes injection, is used for the treatment of tumor; Wherein, every pastille 0.24g; Each 1, every day 2 times.
Embodiment 6:
Get EGC900g, ECG300g adds conventional adjuvant, according to common process, makes capsule, is used for the treatment of tumor; Wherein, every pastille 0.45g; Each 1, every day 2 times.
Embodiment 7:
Get EGC800g, ECG400g adds conventional adjuvant, according to common process, makes drop pill, is used for the treatment of tumor; Wherein, every ball pastille 0.04g; Each 10 balls, every day 1-2 time.
Embodiment 8:
Get EGC840g, ECG210g adds conventional adjuvant, according to common process, makes oral liquid, is used for the treatment of tumor; Wherein, every pastille 0.42g; Each 1, every day 2 times.
Embodiment 9:
Get EGC720g, ECG480g adds conventional adjuvant, according to common process, makes granule, is used for the treatment of tumor; Wherein, every bag of pastille 0.36g; Each 1 bag, every day 2 times.
Embodiment 10:
Get EGC900g, ECG200g adds conventional adjuvant, according to common process, makes injection, is used for the treatment of tumor; Wherein, every pastille 0.45g; Each 1, every day 2 times.
Embodiment 11:
Get ECG450g, EC450g adds conventional adjuvant, according to common process, makes capsule, is used for the treatment of tumor; Wherein, every pastille 0.45g; Each 1, every day 1 time.
Embodiment 12:
Get ECG360g, EC600g adds conventional adjuvant, according to common process, makes drop pill, is used for the treatment of tumor; Wherein, every ball pastille 0.018g; Each 10 balls, every day 2 times.
Embodiment 13:
Get ECG720g, EC600g adds conventional adjuvant, according to common process, makes oral liquid, is used for the treatment of tumor; Wherein, every pastille 0.36g; Each 1, every day 2 times.
Embodiment 14:
Get ECG480g, EC600g adds conventional adjuvant, according to common process, makes granule, is used for the treatment of tumor; Wherein, every bag of pastille 0.24g; Each 1 bag, every day 1-2 time.
Embodiment 15:
Get ECG260g, EC520g adds conventional adjuvant, according to common process, makes injection, is used for the treatment of tumor; Wherein, every pastille 0.13g; Each 1, every day 2 times.
Claims (7)
1. an antineoplastic pharmaceutical compositions is characterized in that the crude drug of this pharmaceutical composition consists of: several theine of epi-nutgall: L-Epicatechin gallate=1-5: 1.
2. a kind of antineoplastic pharmaceutical compositions as claimed in claim 1 is characterized in that the crude drug of this pharmaceutical composition consists of: epigallo catechin: L-Epicatechin gallate=3: 1,2: 1 or 4: 1.
3. a kind of antineoplastic pharmaceutical compositions as claimed in claim 1 or 2, it is characterized in that this pharmaceutical composition is on the basis of said ratio, according to the formulation method of routine, it is prepared into capsule, drop pill, tablet, granule, oral liquid or injection.
4. the application of a kind of antineoplastic pharmaceutical compositions as claimed in claim 1 or 2 in the medicine of preparation treatment human lung adenocarcinoma, melanoma piece, ascites tumour and breast carcinoma.
5. application as claimed in claim 4 is characterized in that wherein antitumor action is meant the tumor control rate of raising to melanoma piece class transplanted tumor.
6. application as claimed in claim 4 is characterized in that wherein antitumor action is meant the tumor control rate of raising to breast carcinoma class transplanted tumor.
7. application as claimed in claim 4 is characterized in that wherein antitumor action is meant the tumor control rate of raising to ascites tumor class transplanted tumor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101194269A CN101095672B (en) | 2007-07-24 | 2007-07-24 | Novel pharmacy use of medicinal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101194269A CN101095672B (en) | 2007-07-24 | 2007-07-24 | Novel pharmacy use of medicinal composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101095672A CN101095672A (en) | 2008-01-02 |
| CN101095672B true CN101095672B (en) | 2011-02-09 |
Family
ID=39009894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101194269A Expired - Fee Related CN101095672B (en) | 2007-07-24 | 2007-07-24 | Novel pharmacy use of medicinal composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101095672B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101984965A (en) * | 2010-11-18 | 2011-03-16 | 安徽农业大学 | Application of epicatechin gallate and derivatives thereof for treating or preventing myocardial infarction and other ischemic heart diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1444935A (en) * | 2002-05-09 | 2003-10-01 | 华东理工大学 | Application of Epigallocatechin gallate (EGCG) in anti-tumor medicine |
-
2007
- 2007-07-24 CN CN2007101194269A patent/CN101095672B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1444935A (en) * | 2002-05-09 | 2003-10-01 | 华东理工大学 | Application of Epigallocatechin gallate (EGCG) in anti-tumor medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101095672A (en) | 2008-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101485655B (en) | Application of dihydromyricetin in preparing medicament for preventing and treating adverse reaction of tumor chemoradiotherapy | |
| CN109575100A (en) | Glycocholic acid application in preparation of anti-tumor drugs | |
| CN101965185A (en) | Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors | |
| CN105476996A (en) | Application of curcumin and afatinib for combined treatment of non-small cell lung cancer | |
| CN101095672B (en) | Novel pharmacy use of medicinal composition | |
| CN103893188A (en) | Application of ilexgenin A in preparation of anti-tumor medicaments | |
| CN109620836B (en) | Compound pharmaceutical composition with breast cancer resistance, application thereof and medicine based on composition | |
| CN101791363A (en) | Broad spectrum anticancer vegetable drug, preparation method and application thereof | |
| CN103463098B (en) | Application of hederagenin for preparing antineoplastic drugs | |
| CN102100729B (en) | Oral administration medicament for treating and preventing radiation damage | |
| CN102232957B (en) | Use of 3-acetoxyl-8, 24-lanostadiene-21-acid in preparing medicines for preventing or treating liver cancer or breast cancer | |
| CN105147695A (en) | Anti-breast cancer powder containing metformin hydrochloride and gdc 0941 | |
| CN105267793B (en) | A kind of new application of Chinese medicine composition | |
| CN103877126B (en) | Knurl lid intends the pharmaceutical usage of shelf fungus and the pharmaceutical composition for the treatment of tumour | |
| CN100478009C (en) | Chinese medicine for anti-tumor and its preparing method | |
| CN103933035A (en) | Pharmaceutical composition for treating brain glioma | |
| CN104523698B (en) | Application of the hederagenin in preparation anti-endometrial cancer cell HEC-1 tumour medicine | |
| CN109771430A (en) | Glycocholic acid application in preparation of anti-tumor drugs | |
| CN102688240A (en) | Pharmaceutical composition for treating colorectal cancer | |
| CN109820879A (en) | Antrodia camphorata extract, the preparation method of Antrodia camphorata composition and medical composition | |
| CN108096239A (en) | A kind of pharmaceutical composition for treating glioma and liver cancer | |
| CN102805768A (en) | Application of catclaw buttercup root extract to preparation of anti-lung cancer medicines | |
| CN102309493B (en) | Anti-cancer medicinal composition | |
| CN100478018C (en) | A medicine for treating liver cancer and method for preparing same | |
| CN106727975A (en) | It is a kind of to treat medicine of breast cancer and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110209 Termination date: 20190724 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |